Vemurafenib Recruiting Phase 2 Trials for Melanoma Treatment

RecruitingTreatment2 IdentifierTitleDrugs
NCT02583516Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
NCT02036086Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases